Updated:
Carlsmed
Carlsmed commercializes AI-driven, patient-specific spine surgery implants founded by Mike Cordonnier in 2018, approved by the FDA for lumbar fusion...
Carlsmed
Carlsmed launched in 2018 from Carlsbad, California, founded by medical device veterans Mike Cordonnier and Niall Casey. The company set out to solve an intractable problem in spine surgery: the industry's reliance on off-the-shelf interbody fusion devices that require surgeons to manually shape bone and disc space during the operation. Carlsmed's proprietary platform instead uses a patient's own CT and MRI scans to digitally plan each surgery and 3D-print custom titanium implants. The company's marquee product is the aprevo device, an FDA-cleared lumbar interbody fusion implant that is patient-specific by design. Rather than competing solely on materials science, Carlsmed folds implant manufacturing into a digital therapeutic workflow — the surgeon uploads imaging, receives a surgical plan within days, and takes delivery of a sterile implant machined to that plan. The platform covers multiple segments of the lumbar spine, with indications that include degenerative disc disease, spondylolisthesis, and stenosis. This convergence of surgical planning software and additive manufacturing puts the company at the center of the personalized surgery movement, a domain investors have backed heavily in orthopedics. Carlsmed raised approximately $65 million in total funding as of 2023, including a $52.5 million Series C round led by Baird Capital and SV Health Investors (per the firm, May 2023). The company has disclosed distribution agreements covering parts of the United States, and its regulatory pathway through the FDA's 510(k) clearance for aprevo in 2021 opened the core US spine market — a segment that industry analysts at EvaluateMedTech projected to grow above $15 billion globally. The firm operates from its Southern California headquarters, where engineering, imaging analysis, and manufacturing are co-located, a design intended to tighten the feedback loop between surgeon input and device production. What separates Carlsmed's architecture from traditional spine implant companies is that the surgical planning software is not an adjunct to the implant — the implant is a downstream output of the software. This makes every case a proprietary data point that can potentially improve future planning models, something no off-the-shelf implant manufacturer can replicate without fundamentally restructuring their production line. The company is structurally closer to an AI-enabled contract manufacturer than to a conventional device distributor, a posture that carries both higher regulatory burden and potentially higher surgical stickiness once integrated into a hospital's workflow.
General information
Firm type
Unclassified
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Mike Cordonnier
Co-Founder & CEO
Niall Casey
Co-Founder & CFO
Sector focus
Frequently asked questions
How does Carlsmed's implant differ from off-the-shelf spinal hardware?
Carlsmed manufactures the aprevo device, a lumbar interbody fusion implant that is individually planned and machined for each patient using their preoperative CT and MRI scans — contrasting with traditional implants that come in fixed sizes and geometries requiring surgical adaption. This approach aims to improve implant-to-endplate match and reduce the need for manual bone removal. The technology received FDA 510(k) clearance in 2021.
What is Carlsmed's regulatory posture in the United States?
Carlsmed pursued the 510(k) clearance pathway through the FDA, receiving authorization for the aprevo system in 2021. As a patient-specific device manufactured from imaging data, the firm's workflow intersects both device regulation and software-as-a-medical-device considerations — a space the FDA has been clarifying through its digital health pre-certification program and related guidance.
How does Carlsmed generate proprietary value from surgical outcomes?
Every aprevo case begins with a digital surgical plan that incorporates the specific patient anatomy, which creates a dataset linking preoperative imaging to the resulting implant design and postoperative results. Over time, that dataset can be used to refine the planning algorithms — a closed-loop learning system that adds clinical value beyond the physical device itself and that a purely hardware-focused manufacturer cannot easily replicate.
Who are the principal investors in Carlsmed?
As of the firm's 2023 Series C round, announced investors include Baird Capital and SV Health Investors who co-led the $52.5 million raise. The round followed earlier financing from a syndicate of medtech-focused venture firms that have publicly disclosed backing the company.
Does Carlsmed sell its software independently of the implant?
The firm positions its software as an integral component of the aprevo device system, not as a standalone product. The surgical plan directly drives the implant's geometric specification, so the revenue model is tied to the implant sale rather than to pure software licensing — aligning the company more closely with medtech reimbursement frameworks than with health IT per-seat pricing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: